NasdaqGS - Nasdaq Real Time Price USD
Crinetics Pharmaceuticals, Inc. (CRNX)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 5:18 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 13 | 14 | 13 |
| Avg. Estimate | -0.91 | -0.93 | -3.69 | -3.86 |
| Low Estimate | -1.03 | -1.07 | -3.91 | -4.51 |
| High Estimate | -0.74 | -0.75 | -3.34 | -2.85 |
| Year Ago EPS | -1.01 | -0.9 | -3.69 | -3.69 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 11 | 12 |
| Avg. Estimate | 240k | 740k | 1.99M | 11.85M |
| Low Estimate | -- | -- | 1M | 3M |
| High Estimate | 1M | 5M | 6M | 57M |
| Year Ago Sales | 120k | -- | 4.01M | 1.99M |
| Sales Growth (year/est) | 100.00% | -- | -50.40% | 495.50% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.86 | -0.86 | -0.81 | -0.86 |
| EPS Actual | -1.01 | -0.9 | -0.93 | -0.94 |
| Difference | -0.15 | -0.04 | -0.12 | -0.08 |
| Surprise % | -17.40% | -4.70% | -14.80% | -9.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.91 | -0.93 | -3.69 | -3.86 |
| 7 Days Ago | -0.91 | -0.93 | -3.7 | -3.89 |
| 30 Days Ago | -0.91 | -0.93 | -3.7 | -3.89 |
| 60 Days Ago | -0.91 | -0.93 | -3.7 | -3.95 |
| 90 Days Ago | -0.88 | -0.9 | -3.57 | -3.81 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | 1 |
| Up Last 30 Days | -- | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CRNX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 9.90% | -- | -- | 3.70% |
| Next Qtr. | -3.30% | -- | -- | 7.90% |
| Current Year | 0.00% | -- | -- | 2.50% |
| Next Year | -4.60% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.88% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 9/27/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/16/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/9/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 8/9/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 7/9/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 7/2/2024 |
Related Tickers
EWTX Edgewise Therapeutics, Inc.
35.57
+0.17%
ACLX Arcellx, Inc.
96.86
+1.67%
JANX Janux Therapeutics, Inc.
50.03
+0.44%
NMRA Neumora Therapeutics, Inc.
16.49
-2.77%
CYTK Cytokinetics, Incorporated
54.97
+0.81%
KYMR Kymera Therapeutics, Inc.
46.41
+0.35%
RVMD Revolution Medicines, Inc.
50.43
+0.86%
PRAX Praxis Precision Medicines, Inc.
73.20
-2.30%
STOK Stoke Therapeutics, Inc.
13.00
-2.03%
BHVN Biohaven Ltd.
52.96
+2.56%